Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1985 1
1987 2
1988 3
1991 1
1996 1
1997 1
1998 2
1999 1
2000 1
2001 1
2002 2
2003 3
2004 1
2005 2
2006 1
2009 2
2010 1
2011 1
2012 1
2013 1
2016 2
2017 2
2018 2
2019 7
2020 2
2021 9
2022 3
2023 4
2024 6
2025 6

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

70 results

Results by year

Filters applied: . Clear all
Page 1
Showing results for im brk
Search for Im BPK instead (1 results)
ACK1 and BRK non-receptor tyrosine kinase deficiencies are associated with familial systemic lupus and involved in efferocytosis.
Guillet S, Lazarov T, Jordan N, Boisson B, Tello M, Craddock B, Zhou T, Nishi C, Bareja R, Yang H, Rieux-Laucat F, Fregel Lorenzo RI, Dyall SD, Isenberg D, D'Cruz D, Lachmann N, Elemento O, Viale A, Socci ND, Abel L, Nagata S, Huse M, Miller WT, Casanova JL, Geissmann F. Guillet S, et al. Elife. 2024 Nov 21;13:RP96085. doi: 10.7554/eLife.96085. Elife. 2024. PMID: 39570652 Free PMC article.
Using a forward genetic screen in multiplex families with SLE, we identified an association between SLE and compound heterozygous deleterious variants in the non-receptor tyrosine kinases (NRTKs) ACK1 and BRK. Experimental blockade of ACK1 or BRK increased circulati …
Using a forward genetic screen in multiplex families with SLE, we identified an association between SLE and compound heterozygous deleteriou …
Pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057): an open-label, single-arm, multicentre, phase 2 study.
Balar AV, Kamat AM, Kulkarni GS, Uchio EM, Boormans JL, Roumiguié M, Krieger LEM, Singer EA, Bajorin DF, Grivas P, Seo HK, Nishiyama H, Konety BR, Li H, Nam K, Kapadia E, Frenkl T, de Wit R. Balar AV, et al. Lancet Oncol. 2021 Jul;22(7):919-930. doi: 10.1016/S1470-2045(21)00147-9. Epub 2021 May 26. Lancet Oncol. 2021. PMID: 34051177 Clinical Trial.
STAT5 and STAT3 balance shapes dendritic cell function and tumour immunity.
Zhou J, Tison K, Zhou H, Bai L, Acharyya RK, McEachern D, Metwally H, Wang Y, Pitter M, Choi JE, Vatan L, Liao P, Yu J, Lin H, Jiang L, Wei S, Gao X, Grove S, Parolia A, Cieslik M, Kryczek I, Green MD, Lin JX, Chinnaiyan AM, Leonard WJ, Wang S, Zou W. Zhou J, et al. Nature. 2025 Jul;643(8071):519-528. doi: 10.1038/s41586-025-09000-3. Epub 2025 May 14. Nature. 2025. PMID: 40369063 Free PMC article.
Targeting of intracellular oncoproteins with peptide-centric CARs.
Yarmarkovich M, Marshall QF, Warrington JM, Premaratne R, Farrel A, Groff D, Li W, di Marco M, Runbeck E, Truong H, Toor JS, Tripathi S, Nguyen S, Shen H, Noel T, Church NL, Weiner A, Kendsersky N, Martinez D, Weisberg R, Christie M, Eisenlohr L, Bosse KR, Dimitrov DS, Stevanovic S, Sgourakis NG, Kiefel BR, Maris JM. Yarmarkovich M, et al. Nature. 2023 Nov;623(7988):820-827. doi: 10.1038/s41586-023-06706-0. Epub 2023 Nov 8. Nature. 2023. PMID: 37938771 Free PMC article.
Mutant KRAS peptide targeted CAR-T cells engineered for cancer therapy.
Benton A, Liu J, Poussin MA, Lang Goldgewicht A, Udawela M, Bear AS, Wellhausen N, Carreno BM, Smith PM, Beasley MD, Kiefel BR, Powell DJ Jr. Benton A, et al. Cancer Cell. 2025 Jul 14;43(7):1365-1376.e5. doi: 10.1016/j.ccell.2025.05.006. Epub 2025 Jun 5. Cancer Cell. 2025. PMID: 40480232
BRK confers tamoxifen-resistance in breast cancer via regulation of tyrosine phosphorylation of CDK1.
Mandapati A, Ning Z, Baharani A, Lukong KE. Mandapati A, et al. Cell Signal. 2023 Aug;108:110723. doi: 10.1016/j.cellsig.2023.110723. Epub 2023 May 20. Cell Signal. 2023. PMID: 37216999
Tam-resistance, however, presents a challenge and the mechanisms that drive it have yet to be fully elucidated. The non-receptor tyrosine kinase BRK/PTK6 is a promising candidate as previous research has shown that BRK knockdown resensitizes Tam-resistant breast can …
Tam-resistance, however, presents a challenge and the mechanisms that drive it have yet to be fully elucidated. The non-receptor tyrosine ki …
STAP-2 is phosphorylated at tyrosine-250 by Brk and modulates Brk-mediated STAT3 activation.
Ikeda O, Miyasaka Y, Sekine Y, Mizushima A, Muromoto R, Nanbo A, Yoshimura A, Matsuda T. Ikeda O, et al. Biochem Biophys Res Commun. 2009 Jun 19;384(1):71-5. doi: 10.1016/j.bbrc.2009.04.076. Epub 2009 Apr 23. Biochem Biophys Res Commun. 2009. PMID: 19393627 Free article.
In the present study, we identified tyrosine-250 (Tyr250) in STAP-2 as a major site of phosphorylation by Brk, using a series of STAP-2 YF mutants and anti-phospho-STAP-2 Tyr250 antibody. Furthermore, overexpression of the STAP-2 Y250F mutant protein affected Brk-me …
In the present study, we identified tyrosine-250 (Tyr250) in STAP-2 as a major site of phosphorylation by Brk, using a series of STAP …
Taxol Induces Brk-dependent Prosurvival Phenotypes in TNBC Cells through an AhR/GR/HIF-driven Signaling Axis.
Regan Anderson TM, Ma S, Perez Kerkvliet C, Peng Y, Helle TM, Krutilina RI, Raj GV, Cidlowski JA, Ostrander JH, Schwertfeger KL, Seagroves TN, Lange CA. Regan Anderson TM, et al. Mol Cancer Res. 2018 Nov;16(11):1761-1772. doi: 10.1158/1541-7786.MCR-18-0410. Epub 2018 Jul 10. Mol Cancer Res. 2018. PMID: 29991529 Free PMC article.
Brk was robustly induced following exposure of TNBC model systems to chemotherapeutic agents (Taxol or 5-fluorouracil) and growth in suspension [ultra-low attachment (ULA)]. ...Mechanistically, AhR and GR copurified and following chemotherapy and ULA, these factors assembl …
Brk was robustly induced following exposure of TNBC model systems to chemotherapeutic agents (Taxol or 5-fluorouracil) and growth in …
BRK tyrosine kinase expression in a high proportion of human breast carcinomas.
Barker KT, Jackson LE, Crompton MR. Barker KT, et al. Oncogene. 1997 Aug 14;15(7):799-805. doi: 10.1038/sj.onc.1201241. Oncogene. 1997. PMID: 9266966
Expression of BRK in fibroblasts and mammary epithelial cells has been shown to enhance their ability to grow anchorage independently, and mammary epithelial cells expressing BRK acquire a potentiated mitogenic response to epidermal growth factor. ...Whereas BRK …
Expression of BRK in fibroblasts and mammary epithelial cells has been shown to enhance their ability to grow anchorage independently …
Involvement of STAP-2 in Brk-mediated phosphorylation and activation of STAT5 in breast cancer cells.
Ikeda O, Mizushima A, Sekine Y, Yamamoto C, Muromoto R, Nanbo A, Oritani K, Yoshimura A, Matsuda T. Ikeda O, et al. Cancer Sci. 2011 Apr;102(4):756-61. doi: 10.1111/j.1349-7006.2010.01842.x. Epub 2011 Jan 23. Cancer Sci. 2011. PMID: 21205088 Free article.
Here, we examined the involvement of STAP-2 in Brk-mediated STAT5 activation in breast cancer cells. Ectopic expression of STAP-2 induced Brk-mediated transcriptional activity of STAT5. Furthermore, STAP-2-knockdown in T47D breast cancer cells induced a marked decre …
Here, we examined the involvement of STAP-2 in Brk-mediated STAT5 activation in breast cancer cells. Ectopic expression of STAP-2 ind …
70 results